These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24328666)

  • 1. A longitudinal analysis of the effect of nonmedical exemption law and vaccine uptake on vaccine-targeted disease rates.
    Yang YT; Debold V
    Am J Public Health; 2014 Feb; 104(2):371-7. PubMed ID: 24328666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric disease burden and vaccination recommendations: understanding local differences.
    Gentile A; Bhutta Z; Bravo L; Samy AG; Garcia RD; Hoosen A; Islam T; Karimi A; Salem M; Simasathien S; Sohail A; Watanaveeradej V; Wiedenmayer K; Schmitt HJ
    Int J Infect Dis; 2010 Aug; 14(8):e649-58. PubMed ID: 20181506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).
    Bar-On ES; Goldberg E; Hellmann S; Leibovici L
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD005530. PubMed ID: 22513932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric immunizations.
    Edwards KM
    Curr Probl Pediatr; 1993; 23(5):186-209. PubMed ID: 8354078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reported vaccine-preventable diseases--United States, 1993, and the childhood immunization initiative.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1994 Feb; 43(4):57-60. PubMed ID: 8295625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).
    Bar-On ES; Goldberg E; Fraser A; Vidal L; Hellmann S; Leibovici L
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005530. PubMed ID: 19588375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From the Centers for Disease Control and Prevention. Reported vaccine-preventable diseases--United States, 1993, and the childhood immunization initiative.
    JAMA; 1994 Mar; 271(9):651-2. PubMed ID: 8309018
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region.
    Dolhain J; Janssens W; Sohn WY; Dindore V; Mukherjee P
    Expert Rev Vaccines; 2019 Sep; 18(9):921-933. PubMed ID: 31328999
    [No Abstract]   [Full Text] [Related]  

  • 11. IMMUNOGENICITY AND SAFETY OF QUINVAXEM® (DIPHTHERIA, TETANUS, WHOLE-CELL PERTUSSIS, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE) GIVEN TO VIETNAMESE INFANTS AT 2 TO 4 MONTHS OF AGE.
    Huu TN; Phuong NT; Toan NT; Thang HV
    Southeast Asian J Trop Med Public Health; 2015 Jul; 46(4):753-63. PubMed ID: 26867396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines.
    Schmitt HJ; von Kries R; Hassenpflug B; Hermann M; Siedler A; Niessing W; Clemens R; Weil J
    Pediatr Infect Dis J; 2001 Aug; 20(8):767-74. PubMed ID: 11734739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Australian childhood immunisation coverage, 1 July to 30 June cohort, assessed as at 30 September 2015.
    Hendry A;
    Commun Dis Intell Q Rep; 2016 Mar; 40(1):E177-8. PubMed ID: 27080025
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic.
    Marshall H; McIntyre P; Roberton D; Dinan L; Hardt K
    Int J Infect Dis; 2010 Jan; 14(1):e41-9. PubMed ID: 19467896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants.
    Lee CY; Thipphawong J; Huang LM; Lee PI; Chiu HH; Lin W; Debois H; Harrison D; Xie F; Barreto L
    Pediatrics; 1999 Jan; 103(1):25-30. PubMed ID: 9917435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations.
    Schmitt HJ; Zepp F; Müschenborn S; Sümenicht G; Schuind A; Beutel K; Knuf M; Bock HL; Bogaerts H; Clemens R
    Eur J Pediatr; 1998 Mar; 157(3):208-14. PubMed ID: 9537487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity, reactogenicity and consistency of production of a Brazilian combined vaccine against diphtheria, tetanus, pertussis and Haemophilus influenzae type b.
    Martins Rde M; Camacho LA; Marcovistz R; Noronha TG; Maia Mde L; dos Santos EM; Barbosa GG; Silva AM; Souza PC; Lemos MC; Homma A
    Mem Inst Oswaldo Cruz; 2008 Nov; 103(7):711-8. PubMed ID: 19057823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children.
    Gatchalian SR; Ramakrishnan G; Bock HL; Lefevre I; Jacquet JM
    Hum Vaccin; 2010 Aug; 6(8):664-72. PubMed ID: 20657177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timeliness of immunisation with the pentavalent vaccine at different levels of the health care system in the Lao People's Democratic Republic: A cross-sectional study.
    Hefele L; Syphan S; Xayavong D; Homsana A; Kleine D; Chanthavilay P; Nouanthong P; Xaydalasouk K; Phathammavong O; Billamay S; Xeuatvongsa A; Reinharz D; Black AP; Muller CP
    PLoS One; 2020; 15(12):e0242502. PubMed ID: 33290386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.